These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1275 related items for PubMed ID: 11326592

  • 1. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY, Ran SP, Weng XM, Li TG, Deng XH, Li FT.
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [Abstract] [Full Text] [Related]

  • 2. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
    Shaw IN, Ebenezer G, Rao GS, Natrajan MM, Balasundaram B.
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
    [Abstract] [Full Text] [Related]

  • 3. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z, Zhang R, Zhou D, Chen J.
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [Abstract] [Full Text] [Related]

  • 4. Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy.
    Soares DJ, Neupane K, Britton WJ.
    Lepr Rev; 1995 Sep; 66(3):210-3. PubMed ID: 7500815
    [Abstract] [Full Text] [Related]

  • 5. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
    Cellona RV, Balagon MF, dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, Topolski R, Gelber RH, Walsh DS.
    Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
    [Abstract] [Full Text] [Related]

  • 6. Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy.
    Chen XS, Li WZ, Jiang C, Ye GY.
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):371-8. PubMed ID: 10700910
    [Abstract] [Full Text] [Related]

  • 7. Dapsone drug resistance in the MDT era.
    Roche PW, Neupane KD, Failbus SS, Butlin CR.
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract] [Full Text] [Related]

  • 8. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR, Shrestha K, Pandey B, Walker SL.
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [Abstract] [Full Text] [Related]

  • 9. Study of rifampicin resistance and comparison of dapsone resistance of M. leprae in pre- and post-MDT era.
    Gupta UD, Katoch K, Katoch VM.
    Indian J Lepr; 2009 Dec; 81(3):131-4. PubMed ID: 20509341
    [Abstract] [Full Text] [Related]

  • 10. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
    Ebenezer GJ, Norman G, Joseph GA, Daniel S, Job CK.
    Indian J Lepr; 2002 Dec; 74(4):301-12. PubMed ID: 12624978
    [Abstract] [Full Text] [Related]

  • 11. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M.
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [Abstract] [Full Text] [Related]

  • 12. Study of multidrug therapy in paucibacillary leprosy.
    Kar PK, Sohi AS.
    J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
    [Abstract] [Full Text] [Related]

  • 13. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
    Mane I, Cartel JL, Grosset JH.
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN, Christian M, Jesudasan K, Kurian N, Rao GS.
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [Abstract] [Full Text] [Related]

  • 15. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
    Biswas S, Mondal KK.
    Indian J Lepr; 2002 Jun; 74(4):313-8. PubMed ID: 12624979
    [Abstract] [Full Text] [Related]

  • 16. Problems of leprosy relapse in China.
    Li HY.
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):1-7. PubMed ID: 8326169
    [Abstract] [Full Text] [Related]

  • 17. Two microbiological relapses in a patient with lepromatous leprosy.
    Chakma JK, Girdhar A, Natrajan M, Kumar A, Girdhar BK.
    Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
    [Abstract] [Full Text] [Related]

  • 18. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
    Cunha Mda G, Virmond M, Schettini AP, Cruz RC, Ura S, Ghuidella C, Viana Fdos R, Avelleira JC, Campos AA, Filho B.
    Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
    [Abstract] [Full Text] [Related]

  • 19. Combined regimens of one year duration in the treatment of multibacillary leprosy--I. Combined regimens with rifampicin administered during one year.
    Pattyn SR, Bourland J, Grillone S, Groenen G, Ghys P.
    Lepr Rev; 1989 Jun; 60(2):109-17. PubMed ID: 2671559
    [Abstract] [Full Text] [Related]

  • 20. Relapses during long-term follow up with drug-susceptible M. leprae among multibacillary leprosy patients treated with multidrug therapy regimens; case reports.
    Thomas A, Hari L, Nagarajan M, Prabhakar R.
    Int J Lepr Other Mycobact Dis; 1995 Sep; 63(3):391-4. PubMed ID: 7594922
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.